Recovery article

AOD-9604 Peptide Dose Reviews: Clinical Insights and Protocols

Key Takeaways AOD-9604 is not FDA-approved and is available for research purposes only. Typical dosing protocols involve subcutaneous injections, often starting with low doses and titrating based on response. Medical supervision is crucial, given the research-

By Recovery & Performance Peptides Editorial Team Published June 21, 2026

Key Takeaways

AOD-9604 is not FDA-approved and is available for research purposes only.

Typical dosing protocols involve subcutaneous injections, often starting with low doses and titrating based on response.

Medical supervision is crucial, given the research-only status and potential side effects.

Dosing may vary based on factors such as body weight and treatment goals.

Missed doses should be managed according to clinical guidelines to maintain consistency.

What Is AOD-9604?

AOD-9604 is a synthetic peptide derived from the C-terminus of human growth hormone, specifically the amino acids 177–191. It is primarily used in metabolic research, focusing on lipid and glucose metabolism modulation. For more detailed information, visit the full profile.

Standard Dosing Protocols

AOD-9604 is not approved by the FDA for any therapeutic use and is available only for research purposes (PMID 15134286). Clinical studies have explored various dosing protocols, typically involving subcutaneous injections. Research protocols often start with doses ranging from 0.25 mg to 1 mg per day, depending on the study's objectives and subject characteristics.

Titration Schedules

Titration of AOD-9604 dosing is essential to balance efficacy and tolerability. Initial doses may start at the lower end of the spectrum, with gradual increases over several weeks. This approach helps to monitor patient response and minimize potential side effects. Titration schedules are often informed by preclinical and clinical trial data, although specific timelines can vary.

Administration Method

AOD-9604 is administered via subcutaneous injection. This method requires knowledge of proper injection techniques, including site rotation to prevent tissue damage. Common sites include the abdomen or thigh. Users should use a fine needle gauge, typically 29 to 31, and ensure proper storage of the peptide, usually in a refrigerated environment until reconstitution.

Factors That Affect Dosing

Several factors can influence AOD-9604 dosing, including body weight, specific metabolic goals, and concurrent medications. Providers may adjust doses based on these variables and assess kidney or liver function to avoid potential complications.

What Happens If You Miss a Dose

If a dose of AOD-9604 is missed, it is generally recommended to take it as soon as remembered unless it is close to the time of the next dose. In such cases, skipping the missed dose and resuming the regular schedule is advised to prevent double dosing.

Dosing Compared to Similar Peptides

AOD-9604 is often compared to other growth hormone-related peptides like BPC-157 and TB-500, which are used for tissue regeneration and repair. While these peptides share some pathways, their dosing and clinical applications differ significantly due to their distinct mechanisms of action (PMID 41490200).

What the Evidence Does Not Show

Current research on AOD-9604 is limited to preclinical and early-phase clinical trials. Long-term safety and efficacy data are lacking, and its use is confined to research settings. More extensive studies are needed to fully understand its potential therapeutic applications and safety profile (PMID 15134286).

FAQ

What is the typical starting dose for AOD-9604? Typical starting doses range from 0.25 mg to 1 mg per day, depending on the research protocol and subject characteristics.

How is AOD-9604 administered? AOD-9604 is administered via subcutaneous injection, typically in the abdomen or thigh, using a fine needle.

Can AOD-9604 be used for weight loss? While AOD-9604 is studied for its effects on lipid metabolism, it is not approved for weight loss treatment and is used only in research settings.

What should I do if I miss a dose? If a dose is missed, take it as soon as possible unless it is near the time for the next dose. Avoid double dosing.

Are there any known side effects of AOD-9604? As a research peptide, detailed side effect profiles are not fully established, but potential side effects may include injection site reactions and metabolic changes.

Medical Disclaimer This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing in a Research Context

Because AOD-9604 is not an approved medicine, there is no established therapeutic dose, and the figures that circulate come from the historical trial protocols and from research-chemical convention rather than from any regulatory label. This section is descriptive and strictly educational, not a usage recommendation. The human efficacy trials used oral AOD-9604, with dose arms spanning roughly 0.25 mg to 30 mg once daily across the two studies.3 A striking and under-appreciated feature of the trial data is that the lower doses (around 1 mg) tended to perform at least as well as the higher ones — an inverted or flat dose-response that is unusual for a drug thought to act through a straightforward receptor-mediated pathway, and that in itself raises questions about how reliably the compound was doing what it was supposed to do. Oral peptide delivery is also notoriously inefficient, since the gut degrades peptides; the fact that development used an oral formulation complicates any attempt to reason from trial doses to the subcutaneous injection favored in contemporary research settings. In non-clinical and research-chemical contexts today, AOD-9604 is typically encountered as a lyophilized powder reconstituted for subcutaneous use, and the microgram-per-injection figures quoted by vendors (commonly a few hundred micrograms) bear no validated relationship to the oral milligram doses used in the actual efficacy trials. This is a crucial honesty point: no one has run a properly po…

Question drills

Open a question for its connected answer.

01Where to find AOD-9604+

At this time, a peptide clinic is your best bet for obtaining pharmaceutical-grade AOD-9604. Some such clinics operate telehealth platforms, allowing you to access the drug without visiting a pharmacy. The only other online channels for the stuff are non-reputable outfits dealing in research-grade peptides, which (let us reiterate) are not fit for human consumption . You might otherwise get it through your doctor, but your likelihood of getting a prescription may depend on their familiarity with a relatively underground medication. As to that point, the medical community’s familiarity with AOD-9604 may grow in the near future. With the government’s push to “unban” peptides, successful reclassification of certain Category 2 drugs could cascade into a broader awareness and acceptance of presently restricted substances such as AOD-9604. Time will tell, and as it does, we’ll update this guide accordingly.

SOURCE / www.innerbody.com ↗

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Tissue and Cartilage Research

Some exploratory trials have studied the peptide’s potential role in: Cartilage regeneration Post-injury recovery Inflammation modulation However, these are preliminary and not validated for medical use.

RESEARCH

Researchers Cited in This Article

The researchers below authored or co-authored publications cited in this article. Listing them here identifies sources; it does not mean they wrote, independently reviewed, sponsored, or endorsed this PeptideDosages.com article. The site author is identified in the article byline.

Product & matchup locker

Linked catalog and comparison files.

Comparison

Claim by Claim: Animal Evidence vs Human Evidence

Every claim on a typical AOD 9604 sales page traces back to one of these rows. Stimulates lipolysis Yes, obese Zucker rats and ob/ob mice (Ng 2000; Heffernan 2001) Not measured as…